论文部分内容阅读
目的:评价痰热清注射液与胸腺肽联用对脑卒中伴肺部感染患者的临床疗效和安全性。方法:选取2013年6月—2015年9月间收治的脑卒中伴肺部感染患者85例,将其分为观察组(45例)和对照组(40例);对照组均给予胸腺肽注射液治疗,观察组患者在对照组基础上加用痰热清注射液治疗,比较两组患者治疗后的总有效率、功能独立性评定(FIM)分及安全性。结果:观察组患者治疗后的总有效率为97.78%(44/45),明显高于对照组为85.00%(34/40)(P<0.05);两组患者治疗后的FIM评分值高于治疗前(P<0.05);观察组患者用药后不良反应的发生率为4.44%(2/45)低于对照组为20.00%(8/40)(P<0.05)。结论:采用痰热清注射液与胸腺肽联用治疗脑卒中伴肺部感染患者的临床疗效优于单用痰热清注射液的疗效,而且安全性较高。
Objective: To evaluate the clinical efficacy and safety of Tanreqing injection and thymosin in patients with stroke and pulmonary infection. Methods: Totally 85 patients with stroke and pulmonary infection who were admitted between June 2013 and September 2015 were divided into the observation group (45 cases) and the control group (40 cases). The control group was given thymosin injection The patients in the treatment group and the observation group were treated with Tanreqing Injection on the basis of the control group. The total effective rate, functional independence (FIM) score and safety were compared between the two groups after treatment. Results: The total effective rate of the observation group was 97.78% (44/45), which was significantly higher than that of the control group (85.00%, 34/40) (P <0.05). The FIM scores of the two groups were higher than those of the control group The incidence of adverse reactions in the observation group was 4.44% (2/45) after treatment, which was lower than that in the control group (20.00%, 8/40) (P <0.05). Conclusion: The clinical efficacy of Tanreqing injection combined with thymosin in the treatment of patients with stroke and pulmonary infection is better than that of Tanreqing injection alone, and the safety is better.